[1-乙酰氧基-5-[[(2S,3S,4S,6R)-3-羟基-2-甲基-6-[[(1S,3S)-3,5,12-三羟基-3-(2-羟基乙酰基)-10-甲氧基-6,11-二氧代-2,4-二氢-1H-并四苯-1-基]氧基]四氢吡喃-4-基]氨基]戊基]乙酸酯 | 138967-27-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 中文名称: [1-乙酰氧基-5-[[(2S,3S,4S,6R)-3-羟基-2-甲基-6-[[(1S,3S)-3,5,12-三羟基-3-(2-羟基乙酰基)-10-甲氧基-6,11-二氧代-2,4-二氢-1H-并四苯-1-基]氧基]四氢吡喃-4-基]氨基]戊基]乙酸酯
• 中文别名: 2,6,7-三氧杂二环(2.2.2)辛烷,1-(4-(苯基乙炔基)苯基)-4-丙基-
• 英文名称: N-(5,5-diacetoxypentyl)doxorubicin
• 英文别名: N-(5,5-diacetoxy-pent-1-yl)doxorubicin；Dapdox；[1-acetyloxy-5-[[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]amino]pentyl] acetate
• CAS: 138967-27-8
• 化学式: C₃₆H₄₃NO₁₅
• 分子量: 729.735
• InChiKey: RBQJFBGSQDDJKT-YTHWRKCVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  52
• 可旋转键数：
  15
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  245
• 氢给体数：
  6
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  6-马来酰亚胺己酸肼 、 [1-乙酰氧基-5-[[(2S,3S,4S,6R)-3-羟基-2-甲基-6-[[(1S,3S)-3,5,12-三羟基-3-(2-羟基乙酰基)-10-甲氧基-6,11-二氧代-2,4-二氢-1H-并四苯-1-基]氧基]四氢吡喃-4-基]氨基]戊基]乙酸酯 、 三氟乙酸 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  BR96 conjugates of highly potent anthracyclines

  摘要：

  The 6-maleimidocaproylhydrazone derivatives of highly potent antitumor agents 5-Diacetoxypentyidoxorubicin and Morpholinodoxorubicin were synthesized and conjugated to monoclonal antibody BR96 and control IgG. Immunoconjugate molar ratios were generally 7.5-8.5, and dimer aggregate levels were low. The linkers released parent drug at lysosomal pH 5, while they remained stable at neutral pH. BR96 conjugates were highly potent and antigen specific in vitro. The BR96-DAPDOX conjugate demonstrated an IC50 of 0.03 mum, and was at least 300-fold more potent than a non-binding IgG-DAPDOX control conjugate. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00375-5
• 作为产物：
  描述：

  5-己烯醛 在 二甲基硫 、 三氟化硼乙醚 、 sodium cyanoborohydride 、 臭氧 作用下， 以 四氢呋喃 、 乙醚 、 水 、 乙腈 为溶剂， 反应 1.17h， 生成 [1-乙酰氧基-5-[[(2S,3S,4S,6R)-3-羟基-2-甲基-6-[[(1S,3S)-3,5,12-三羟基-3-(2-羟基乙酰基)-10-甲氧基-6,11-二氧代-2,4-二氢-1H-并四苯-1-基]氧基]四氢吡喃-4-基]氨基]戊基]乙酸酯
  参考文献：
  名称：

  N-(5,5-diacetoxypent-1-yl)doxorubicin: a new intensely potent doxorubicin analog

  摘要：

  N-(5,5-Diacetoxypent-1-yl)doxorubicin (DAPDOX) (3), a new, water-soluble analogue of doxorubicin, has been synthesized by coupling doxorubicin with 5-oxopentane-1,1-diacetate in the presence of NaBH3CN. This analogue was designed to be converted to the corresponding aldehyde, N-(5-oxopent-1-yl)doxorubicin, in the presence of carboxylate hydrolases, enzymes that are ubiquitous in tissue. DAPDOX had a half-life of several days in 0.05 M phosphate or 0.05 M acetate buffer solution at pH 4.0. However, in 0.05 M phosphate buffer at pH 7.4 in the presence of 20 unit equiv of porcine liver carboxylate esterase, the half-life of DAPDOX was less than 1 min. N-(5-acetoxypent-1-yl)doxorubicin (4), which should give rise to N-(5-hydroxypent-1-yl)doxorubicin on esterase-mediated hydrolysis, and N-(pent-1-yl)doxorubicin (5), were also prepared for comparative biological studies. DAPDOX was 150 times more potent than doxorubicin at inhibiting the growth of Chinese hamster ovary (CHO) cells in culture. The compound retained the same degree of potency against a CHO subline 100-fold resistant to doxorubicin (CHO/DOX) that expressed elevated levels of P-glycoprotein. Compounds 4 and 5, on the other hand, were no more effective than doxorubicin at inhibiting the growth of CHO cells and were 4-7-fold less potent against the CHO/DOX subline. DAPDOX is representative of a new structural class of doxorubicin analogues with unique chemical and biological properties.

  DOI：

  10.1021/jm00095a017

文献信息

• Intensely Potent Doxorubicin Analogues:  Structure−Activity Relationship
  作者：David Farquhar、Abdallah Cherif、Elena Bakina、J. Arly Nelson

  DOI：10.1021/jm9706980

  日期：1998.3.1

  N-(5,5-Diacetoxypent-1-yl)doxorubicin (1b) is an intensely cytotoxic doxorubicin analogue that retains full potency against tumor cells that express elevated levels of P-glycoprotein and are resistant to doxorubicin. 1b was designed to be hydrolyzed in the presence of carboxylate esterases to N-(5-oxypent-1-yl)doxorubicin, an aldehyde capable of existing in equilibrium with a cyclic carbinolamine. To investigate the structural determinants of potency for 1b, we have prepared a series of chemically related compounds in which various omega-[bis(acetoxy)]alkyl or omega-[bis(acetoxy)]alkoxyalkyl groups are substituted at the 3'-amino position of the daunosamine sugar. These groups were selected to assess the effect of chain length, oxygen substitution, and carbinolamine ring size on analogue potency. The compounds were evaluated for their ability to inhibit the in vitro growth of the following cell lines: (a) Chinese hamster ovary (CHO) cells, (b) a CHO cell mutant 100-fold resistant to doxorubicin that expresses elevated levels of P-glycoprotein, (c) a murine ductal cell pancreatic adenocarcinoma (Pane 02), and (d) a murine mammary carcinoma (CA 755). The most potent members of the series were those that could form a straight chain aldehyde intermediate after esterase-mediated hydrolysis of the omega-bis(acetoxy) groups and give rise to 5- or 6-membered ring carbinolamines. Analogues capable of forming 7-, 8-, or 9-membered carbinolamines were markedly less active. The N-methyl derivative of 1b, which cannot give rise to a cyclic carbinolamine, was 2 orders of magnitude less potent than 1b. A branched chain analogue, If, which contained a tertiary carbon atom adjacent to the omega-bis(acetoxy) groups, was also substantially less active than its nonbranched counterpart, 1a. These findings suggest that the chain length of the 3'-amino substituents and the ability of the derived aldehydes to form 5- or 6-membered carbinolamines are critical determinants of biologic potency.